Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 8:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 1,429 matching trials from the live ClinicalTrials.gov search.
Conditions
Hypoglycemia
Interventions
Naltrexone High Dose, Naltrexone Low Dose
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Hypoxic-Ischemic Encephalopathy, Pain
Interventions
Dexmedetomidine Hydrochloride, Morphine Sulfate
Drug
Lead sponsor
University of Utah
Other
Eligibility
Up to 24 Hours
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
5
States / cities
Murray, Utah • Ogden, Utah • Provo, Utah + 1 more
Conditions
Pain, Postoperative
Interventions
Bupivacaine, Dexamethasone
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Prescription Opiate/Medication Dependence
Interventions
Vivitrol
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 60 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Post Surgical Pain
Interventions
2mg Dexamethasone, 4mg Dexamethasone, Ropivacaine (TAP blocks), Morphine, Bupivacaine Hydrochloride, Normal saline 1ml, Normal saline 0.5ml
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Advanced Solid Tumor
Interventions
Sitravatinib, Warfarin, Dextromethorphan, Midazolam, Digoxin, Rosuvastatin, Nivolumab
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Goshen, Indiana • Austin, Texas • San Antonio, Texas + 2 more
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Titration of Intravenous Hydromorphone

NCT01892709
Conditions
Acute Severe Pain
Interventions
Hydromorphone
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
21 Years to 64 Years
Enrollment
215 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Burlington, Vermont
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Naltrexone-Bupropion-Methamphetamine Interaction Study

NCT01359930
Conditions
Methamphetamine Dependence
Interventions
placebo, Naltrexone and Bupropion SR
Other · Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Francisco, California
Conditions
End Stage Renal Disease, Chronic Pain, Opioid Dependence
Interventions
Pain Coping Skills Training (PCST), Buprenorphine
Behavioral · Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
16
States / cities
West Haven, Connecticut • Chicago, Illinois • Boston, Massachusetts + 11 more
Conditions
Post Traumatic Stress Disorder, Alcohol Abuse
Interventions
2mg Buprenex and 380mg Vivitrol, Placebo (SL pill qd, IM injection q4weeks)
Drug
Lead sponsor
Pharmacotherapies for Alcohol and Substance Use Disorders Alliance
Other
Eligibility
18 Years to 70 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Tuscaloosa, Alabama • West Haven, Connecticut
Conditions
Acute Pain
Interventions
H2O, 1+1
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
21 Years to 65 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Heroin Dependence, Opioid-Related Disorders
Interventions
Hydromorphone
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Detroit, Michigan
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Behavioral Effects of Opioids and Alcohol

NCT04300751
Conditions
Opioid Use, Alcohol Drinking
Interventions
Alcohol, Opioid Agonist
Drug
Lead sponsor
Sharon Walsh
Other
Eligibility
21 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Lexington, Kentucky
Completed Phase 1 Interventional Accepts healthy volunteers

Abuse Potential Study of PF-00345439

NCT01986283
Conditions
Opioid Users
Interventions
Capsule, PF-00345439, oxycodone
Drug
Lead sponsor
Pain Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Abuse Potential
Interventions
gabapentin 600 mg, gabapentin 1200 mg, gabapentin 600 mg and oxycodone HCl 20 mg, gabapentin 1200 mg and oxycodone HCl 20 mg, oxycodone HCl 20 mg, placebo
Drug
Lead sponsor
Viatris Specialty LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Marlton, New Jersey
Conditions
Opioid-Related Disorders, Substance-Related Disorders
Interventions
Lofexidine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 59 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1997
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Depression, Major Depressive Disorder
Interventions
Buprenorphine, Placebo
Drug
Lead sponsor
Jordan F. Karp
Other
Eligibility
50 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Chronic Low Back Pain
Interventions
ABT-712, Placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
21 Years to 75 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
31
States / cities
Huntsville, Alabama • Burbank, California • San Diego, California + 27 more
Conditions
Drug Use, Opioid-use Disorder
Interventions
Buprenorphine and Outpatient Parenteral Antibiotic Therapy, Buprenorphine and standard of care antibiotic treatment
Drug
Lead sponsor
Laura Fanucchi
Other
Eligibility
18 Years to 99 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Lexington, Kentucky
Not listed No phase listed Observational

Opiate Use and Biliary Dilation

NCT03870347
Conditions
Evaluation of Association Between Opiate Use and Biliary Dilation
Interventions
Endoscopic ultrasound
Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Stanford, California
Conditions
Locally Advanced Head and Neck Cancer
Interventions
Xtampza ER
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Opioid Use Disorder
Interventions
Buprenorphine
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Acute Pain
Interventions
Oxymorphone immediate release
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
21
States / cities
Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 10 more